Hubbry Logo
7-Hydroxymitragynine7-HydroxymitragynineMain
Open search
7-Hydroxymitragynine
Community hub
7-Hydroxymitragynine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
7-Hydroxymitragynine
7-Hydroxymitragynine
7-Hydroxymitragynine
View on Wikipedia
from Wikipedia

7-Hydroxymitragynine
Clinical data
Other names7-OH; 7α-Hydroxy-7H-mitragynine;[1] 9-Methoxycorynantheidine hydroxyindolenine[1]
Dependence
liability		High
Addiction
liability		High[2]
Routes of
administration		Oral
Drug classOpioid
ATC code
  • None
Legal status
Legal status
  • BR: Class F1 (Prohibited narcotics)
  • US: Unscheduled
Pharmacokinetic data
MetabolitesMitragynine pseudoindoxyl
Identifiers
  • Methyl (2E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H30N2O5
Molar mass414.502 g·mol−1
3D model (JSmol)
  • CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(OC)c34)[C@@H]2C[C@@H]1\C(=C/OC)C(=O)OC

  • CC[C@@H]1CN2CC[C@@]3(O)C(=NC4=CC=CC(OC)=C34)[C@@H]2C[C@@H]1\C(=C/OC)C(=O)OC
  • InChI=1S/C23H30N2O5/c1-5-14-12-25-10-9-23(27)20-17(7-6-8-19(20)29-3)24-21(23)18(25)11-15(14)16(13-28-2)22(26)30-4/h6-8,13-15,18,27H,5,9-12H2,1-4H3/b16-13+/t14-,15+,18+,23+/m1/s1 checkY
  • Key:RYENLSMHLCNXJT-CYXFISRXSA-N checkY

7-Hydroxymitragynine (7-OH-MIT, often simply referred to as 7-OH) is a terpenoid indole alkaloid present in the plant Mitragyna speciosa (the leaves of which are commonly known as kratom).[3] It was first described in 1994.[4] In humans, it is produced as an active metabolite of mitragynine via hepatic oxidation.[5] 7-OH exhibits greater binding affinity to μ-opioid receptors (MOR) than mitragynine.[6]

Pharmacology

[edit]

7-OH-MIT, like mitragynine, appears to be a mixed opioid receptor agonist/antagonist, with recent research indicating that it acts as a partial agonist at μ-opioid receptors and as a competitive antagonist at δ- and κ-opioid receptors.[7][8] Both 7-OH-MIT and mitragynine do not appear to activate the β-arrestin pathway, distinguishing it from traditional opiate and opioid chemicals.[7] A study has found the binding affinity of 7-OH-MIT to be μ-opioid receptor (MOR) 37 (± 4) nM and δ-opioid receptor (DOR) 91 (± 8) nM and κ-opioid receptor (KOR) 132 (± 7) nM.[9] Another study found the binding affinity of 7-OH-MIT to be MOR 16 (± 1) nM and DOR 137 (± 21) nM and KOR 133 (± 37) nM.[10] Another study found the binding affinity of 7-OH-MIT to be MOR 13.5 nM, DOR 155 nM, and KOR 123 nM.[10] Cross-tolerance to morphine was evident in mice rendered tolerant to 7-hydroxymitragynine and vice versa. Naloxone-induced withdrawal signs were elicited equally in mice chronically treated with 7-hydroxymitragynine or morphine.[11]

Synthesis

[edit]

In natural kratom leaves, 7-hydroxymitragynine is only present in small amounts, comprising less than 2% of overall alkaloid content.[12] Therefore, extracting 7-OH-MIT in high concentrations directly from natural kratom leaves is not practical. Instead, 7-hydroxymitragynine can be produced semisynthetically via the oxidation of mitragynine.[5]

Society and culture

[edit]

7-OH has been rising in popularity as a recreational drug, particularly in the United States. Its ability to bind to opioid receptors can cause addictive effects. In an electrical stimulation test using guinea-pig ileum, 7-OH performed 13 times greater pain relief than that of morphine.[13] The drug's novelty has meant that it has increasingly been sold unregulated over the counter in gas stations and smoke shops, often in highly concentrated "candy-like" or pill form alongside kratom powder and other supplements with little to no information provided to consumers about its effects.[12]

According to the United States Poison Control Center, the number of cases relating to kratom-based products such as 7-OH have increased from under 200 in 2014 to 1600 in 2024, with approximately 40% of 7-OH reports coming from individuals who were abusing the drug.[14]

[edit]

United States

[edit]

In July 2025, the Food and Drug Administration (FDA) formally recommended that the Drug Enforcement Administration (DEA) classify 7-hydroxymitragynine as a controlled substance.[15][16] This action was publicized to not be targeting Mitragyna speciosa itself.[17] Despite claims by marketers for products that contain 7-OH that they can be used to treat anxiety and pain, the drug is not approved by the FDA for any medical use or as a food supplement.[18]

Research

[edit]

A study on 7-hydroxymitragynine's safety was unable to identify an LD50 orally due to a lack of deaths occurring. In a later part of the same study they found both mitragynine and 7-hydroxymitragynine to be able to cause respiratory depression when given intravenously. This same study also showed seizures in many of the surviving mice from the mitragynine group.[19] 7-Hydroxymitragynine has been described as a "prototypical" compound to develop a new generation of opioids with an improved safety profile.[20]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

7-Hydroxymitragynine

View on Grokipedia
from Grokipedia

7-Hydroxymitragynine is an with the molecular formula C23H30N2O5 that occurs naturally in trace quantities—typically less than 0.05% of dried leaf mass—in the leaves of , a tropical tree native to commonly referred to as kratom. It functions primarily as the active metabolite of , the dominant in kratom, formed through hepatic metabolism , and is responsible for mediating a substantial portion of kratom's opioid-like pharmacological effects. Pharmacologically, 7-hydroxymitragynine acts as a potent at the mu-opioid receptor (), exhibiting approximately 10-fold greater potency than , with a binding affinity (Ki) of around 47 nM and an EC50 of 34.5 nM for human activation, achieving about 47% maximal efficacy relative to full agonists. This selective engagement underlies its properties observed in models, where it contributes to 's antinociceptive effects without fully recapitulating the respiratory depression associated with traditional opioids. Unlike , which displays relatively low affinity and partial antagonistic activity at higher concentrations, 7-hydroxymitragynine demonstrates consistent , highlighting its role as the key pharmacoactive species in kratom's bioactivity. Despite its low endogenous levels, 7-hydroxymitragynine's high potency has drawn attention for potential therapeutic applications in and mitigation, though its contribution to kratom's abuse liability remains a point of empirical scrutiny, with studies indicating rewarding effects in preclinical assays comparable to those of itself. Synthetic analogs and isolated forms have emerged in unregulated markets, amplifying concerns over variability in potency and toxicity, yet peer-reviewed data emphasize its G-protein-biased signaling at , which may confer a differential safety profile relative to conventional opioids.

Chemistry

Chemical Structure and Properties


7-Hydroxymitragynine is a terpenoid indole alkaloid characterized by a polycyclic structure incorporating an indolo[2,3-a]quinolizidine core framework, featuring an ethyl group, methoxy substituents, a methoxymethyl side chain, and a distinctive hydroxy group at the 7-position that differentiates it from its precursor mitragynine. Its molecular formula is C23_{23}H30_{30}N2_{2}O5_{5}, with a molecular weight of 414.50 g/mol. The compound possesses four defined stereocenters, contributing to its specific three-dimensional configuration essential for biological activity. As a lipophilic molecule akin to (logP ≈ 1.73), 7-hydroxymitragynine demonstrates poor aqueous , necessitating dissolution in organic solvents like , , or for experimental handling, while exhibiting limited in due to its basic and non-polar characteristics. This hydrophobicity influences its partitioning behavior in biological systems, though exact logP values for 7-hydroxymitragynine remain less documented compared to . Physical properties such as or points are not widely reported in available chemical databases, reflecting its status as a naturally occurring minor rather than a extensively characterized synthetic compound.

Biosynthesis and Laboratory Synthesis

In Mitragyna speciosa, 7-hydroxymitragynine is produced as a minor monoterpenoid indole alkaloid alongside the predominant alkaloid mitragynine, through a biosynthetic pathway that begins with the condensation of tryptamine and the iridoid glucoside secologanin to form strictosidine via strictosidine synthase. Subsequent enzymatic steps, including Pictet-Spengler cyclization, reductions, and rearrangements mediated by plant-specific cytochrome P450 enzymes and reductases, yield the corynanthe-type scaffold of mitragynine, with 7-hydroxymitragynine arising via site-specific oxidation at the 7-position, likely catalyzed by a P450 monooxygenase, though the precise enzymes and regulatory factors remain incompletely characterized. This hydroxylation step parallels oxidative modifications observed in other indole alkaloid pathways but has been resistant to full reconstruction in heterologous systems like yeast or Escherichia coli, where mitragynine production has been achieved through four key enzymatic transformations. Ongoing research, including NIH-funded efforts, aims to map the complete pathway to enable microbial engineering for scalable production, highlighting gaps in understanding post-mitragynine modifications under varying plant growth conditions such as age, habitat, and stress. Laboratory synthesis of 7-hydroxymitragynine has primarily relied on semi-synthetic routes from , with emerging more recently to address stereochemical complexity and supply limitations. In a seminal semi-synthetic approach reported in 2002, was oxidized using lead tetraacetate to generate an N-oxide intermediate, followed by stereoselective reduction with to afford 7-hydroxymitragynine in moderate yield, providing early access for pharmacological studies. This method exploits the natural abundance of but involves hazardous reagents, prompting exploration of milder biocatalytic or metal-free alternatives. was accomplished in 2022 via a 12-step sequence starting from a chiral cyclohexenone precursor, featuring key steps such as stereocontrolled , intramolecular , and late-stage , achieving an overall yield of 11% for (+)-7-hydroxymitragynine while confirming its . These synthetic advances have facilitated analog generation for structure-activity relationship studies, though scalability remains challenged by the molecule's dense polycyclic architecture and sensitivity to epimerization.

Pharmacology

Mechanism of Action

7-Hydroxymitragynine functions primarily as a partial agonist at the mu-opioid receptor (MOR), mediating its analgesic and opioid-like effects through G-protein-coupled signaling pathways. Radioligand binding assays demonstrate high affinity for MOR, with reported Ki values ranging from 7.9 nM to 77.9 nM in human and rodent models, surpassing that of its precursor mitragynine by approximately 5- to 10-fold. Its antinociceptive potency is approximately 13 times that of morphine in certain preclinical assays, with concentrated forms potentially exhibiting even greater effects. This agonism is antagonized by mu-selective blockers such as naloxone, confirming MOR dependence for antinociceptive activity in preclinical models. Unlike full MOR agonists like morphine, 7-hydroxymitragynine exhibits G-protein bias, preferentially activating G-protein-mediated pathways over β-arrestin recruitment, which correlates with potent analgesia but reduced respiratory depression and tolerance development in rodents. Affinity for delta-opioid (DOR) and kappa-opioid (KOR) receptors is notably lower, with Ki values exceeding 100 nM, rendering these interactions minimal contributors to its primary effects. Unlike , which shows some binding to adrenergic-α2 receptors, 7-hydroxymitragynine lacks significant adrenergic affinity, isolating its activity to mechanisms. Preclinical functional assays, including GTPγS binding and cAMP inhibition, affirm low-efficacy partial at , with maximal around 20-50% of , potentially explaining attenuated side effects like and . Emerging structural studies reveal that 7-hydroxymitragynine binds in a distinct pose compared to classical opioids, engaging key residues like Asp3.32 and His6.55 to stabilize an active conformation favoring G-protein coupling over pathways. This biased signaling profile, validated in β-arrestin knockout models, supports hypotheses of a favorable therapeutic window, though in vivo confirmation remains limited to observational data. No substantial evidence implicates non-opioid receptors, such as serotonin or dopamine systems, in its core mechanism, distinguishing it from broader kratom polypharmacology.

Pharmacokinetics and Metabolism

7-Hydroxymitragynine exhibits rapid oral absorption, with peak plasma concentrations (Cmax) of approximately 56.4 ng/mL achieved within 15 minutes post-dose in dogs following administration of 2 mg/kg. In human studies involving dosing, which yields 7-hydroxymitragynine as a , median time to maximum plasma concentration (Tmax) for 7-hydroxymitragynine ranges from 1.2–1.8 hours after single doses and 1.3–2.0 hours after multiple doses, indicating comparable absorption kinetics when endogenously formed. Its is influenced by gastric instability, with up to 27% degradation in simulated gastric fluid, partially converting to . Distribution of 7-hydroxymitragynine includes penetration into the , as evidenced by measurable brain concentrations in (1.5-fold higher than peak plasma levels at 4 hours post-administration in mice producing effects). data specific to 7-hydroxymitragynine are limited, though related kratom alkaloids show moderate binding. Metabolism of 7-hydroxymitragynine occurs primarily in the liver, but it demonstrates instability in human plasma, undergoing conversion back to , unlike stability observed in or plasma. This degradation, along with further CYP-mediated transformations, contributes to its short , estimated at approximately 2.5 hours in humans. Formation of 7-hydroxymitragynine itself from is catalyzed by hepatic , and inhibition of this enzyme (e.g., by ) elevates 7-hydroxymitragynine exposure, confirming CYP3A dependency. In human liver microsomes, additional metabolites like 9-O-demethylmitragynine derive from related pathways, though 7-hydroxymitragynine-specific downstream products remain undercharacterized. Elimination half-life varies, with mean values of 4.7 hours after single doses and up to 24.7 hours after multiple doses in humans, reflecting accumulation potential. Primary routes include urinary and fecal , consistent with kratom profiles, though quantitative data for 7-hydroxymitragynine alone are sparse. Linear have not been fully established for isolated 7-hydroxymitragynine due to its minor natural abundance and reliance on as precursor.

Natural Occurrence and Sources

Role in Mitragyna speciosa

7-Hydroxymitragynine occurs naturally as a minor alkaloid in the leaves of Mitragyna speciosa, typically comprising less than 0.05% of the dried leaf mass and less than 2% of the total alkaloid content. Its endogenous levels in fresh leaves are generally below 0.01%, with reported values around 0.04% of the alkaloid fraction in some extracts. These low concentrations distinguish it from the dominant alkaloid mitragynine, which constitutes 1–2% of dry leaf weight. Within M. speciosa, 7-hydroxymitragynine is biosynthesized via oxidation of , likely involving enzymes or similar oxidative pathways active in the plant's metabolism. This process integrates it into the plant's profile, though its precise physiological function—such as in defense against herbivores or environmental stressors—has not been definitively established in empirical studies. Concentrations can vary based on factors like leaf age, drying methods, and regional cultivars, with lower drying temperatures preserving integrity but not substantially elevating 7-hydroxymitragynine levels.

Isolation and Concentration in Products

7-Hydroxymitragynine occurs naturally in the leaves of (kratom) at trace levels, typically comprising less than 0.02% of the dry leaf weight and less than 2% of the total content. Concentrations in native leaves vary by strain and origin, ranging from 0.003% to 0.012% in Thai varieties and up to 0.03% to 0.15% in some Malaysian samples, though most analyses report levels around 0.01% to 0.04%. These low natural abundances necessitate extraction and purification techniques to isolate the compound for study or enhancement in products. Isolation of 7-hydroxymitragynine from M. speciosa leaves generally involves solvent extraction followed by chromatographic separation, as it co-occurs with dominant alkaloids like . Common methods include acid-base extraction with solvents such as or , often aided by ultrasonic assistance to improve yield of alkaloids including 7-hydroxymitragynine. Purification typically employs (HPLC) or to separate it from and other minor s, yielding pure fractions for analysis or synthesis precursors. Enzymatic pretreatments with or have been explored to enhance overall alkaloid release from leaf matrices, though specific yields for 7-hydroxymitragynine remain low without further concentration. In commercial kratom products, 7-hydroxymitragynine concentrations are often elevated beyond natural levels through extract standardization or adulteration. Powdered leaf products contain median levels around 0.01% (w/w), with ranges from below detectable limits to 0.21%. Concentrated extracts can reach up to 2% of the alkaloid fraction, though reputable guidelines recommend no more than 2% 7-hydroxymitragynine in total alkaloids to avoid synthetic spiking. Products labeled as "7OH", "7-OH", "70H", or "70OH" commonly refer to concentrated, isolated, or semi-synthetically enhanced forms of 7-hydroxymitragynine, often achieving purities up to 98%, distinct from traditional kratom extracts, which are full-spectrum containing primarily mitragynine with low levels of naturally occurring 7-hydroxymitragynine derived from leaf concentration (<0.1–2% of alkaloids). In contrast, 7OH products emphasize high concentrations of 7-hydroxymitragynine, often semi-synthetic and requiring laboratory processing to achieve elevated potency not attainable from natural sources alone; 7-hydroxymitragynine is 5- to 50-fold more potent than mitragynine at mu-opioid receptors. These products are typically sold as tablets, gummies, shots, or additives, marketed for pain relief, anxiety aid, mood enhancement, or opioid withdrawal support to provide stronger opioid-like effects, often without regulation or clear labeling. Some products have been found with artificially high levels, likely from semi-synthetic conversion of mitragynine or direct addition of laboratory-synthesized 7-hydroxymitragynine, raising concerns about unregulated potency and safety. Variability across products underscores the need for third-party testing, as alkaloid profiles differ widely due to processing methods and source plant genetics.

Empirical Research

Preclinical and Animal Studies

Preclinical studies have demonstrated that 7-hydroxymitragynine (7-OH-MG) acts as a potent mu- , exhibiting dose-dependent antinociceptive effects in models. In mice, of 7-OH-MG produced significant analgesia in the tail-flick and hot-plate tests, with an ED50 value approximately 100-fold lower than that of , indicating higher potency. These effects were antagonized by , confirming mediation. However, investigations using knockout models or inhibitors of its conversion to 7-OH-MG have shown that mitragynine's overall antinociceptive activity in mice largely persists independently of 7-OH-MG formation, suggesting 7-OH-MG's role may be limited despite its potency. Animal studies on tolerance reveal that repeated 7-OH-MG administration induces antinociceptive tolerance in mice, comparable to , along with to other opioids. Chronic dosing also precipitates naloxone-precipitable withdrawal symptoms, including jumping, rearing, and wet-dog shakes, indicative of . In contrast to , which shows minimal tolerance development in some models, 7-OH-MG's profile aligns more closely with classical opioids. Regarding abuse potential, 7-OH-MG facilitates intracranial self-stimulation in rats, lowering reward thresholds in a manner similar to , with effects observed in both males and females. This suggests reinforcing properties mediated by , though the magnitude appears dose-dependent and less pronounced than traditional opioids at equivalent doses. Additional preclinical data indicate 7-OH-MG modulates opioid-induced respiratory depression bidirectionally in , potentially mitigating risks at low doses while exacerbating them at higher concentrations, though mechanisms require further elucidation. Metabolism studies in mice confirm hepatic conversion of to 7-OH-MG, supporting its role as an contributing to kratom's effects.

Human Observational and Clinical Data

Human pharmacokinetic data for 7-hydroxymitragynine (7-OH-MG) have been derived primarily from controlled studies administering kratom leaf powder, where 7-OH-MG serves as a minor of . In a 2024 involving single and multiple oral doses of encapsulated dried kratom (1–3 g per dose, up to 3 g three times daily for 7–14 days), plasma concentrations of 7-OH-MG reached median peak levels (C_max) of 0.5–1.0 ng/mL after single doses and 0.8–1.5 ng/mL after multiple doses, with time to peak (T_max) of 1.2–1.8 hours for single administration and 1.3–2.0 hours for repeated dosing. These low systemic exposures reflect limited from , with 7-OH-MG representing less than 1% of total kratom alkaloids in circulation, though individual variability in CYP3A4-mediated metabolism influences levels. An exploratory safety and neurocognitive study in healthy volunteers receiving chronic low-dose kratom (1 g three times daily for 14 days) confirmed steady-state 7-OH-MG plasma concentrations achieved within 7 days, with no significant adverse effects on cognitive function, mood, or attributed directly to 7-OH-MG; however, the study emphasized that kratom's overall profile, including 7-OH-MG, warrants caution due to partial mu-opioid . Quantification methods via LC-MS/MS in human plasma from kratom trials have validated detection of 7-OH-MG alongside other alkaloids, enabling precise tracking but highlighting its sub-nanomolar potency compared to preclinical models. Direct clinical trials on isolated 7-OH-MG are absent, with available limited to profiling rather than isolated administration, precluding causal attribution of effects solely to 7-OH-MG without from co-occurring kratom compounds. Observational reports from users of concentrated 7-OH-MG products (e.g., extracts marketed as "enhanced kratom") describe opioid-like and analgesia at doses equivalent to 1–5 mg, but these are anecdotal and prone to self-report , lacking controlled verification. Adverse event data include case clusters of serious illnesses linked to 7-OH-MG-containing products, such as seizures, respiratory depression, and organ toxicity reported in September 2025 by health authorities, involving unspecified doses but emphasizing unregulated formulations' risks over natural kratom sources. U.S. FDA assessments in July 2025 noted emerging abuse patterns with 7-OH-MG analogs, citing binding as a mechanistic driver of dependence potential, though incidence remains underreported due to non-medical contexts and diagnostic challenges. No large-scale epidemiological studies exist to quantify population-level prevalence or outcomes specific to 7-OH-MG exposure.

Safety, Toxicity, and Dependence Profiles

Preclinical toxicity studies of 7-hydroxymitragynine indicate relatively low oral and lethality in . In mice, intravenous administration yielded an LD50 of 24.7 mg/kg, with deaths primarily due to respiratory depression occurring within 10 minutes, accompanied by seizures at higher doses. No lethality was observed with oral doses up to 50 mg/kg in mice, suggesting poor gastrointestinal absorption or rapid mitigating acute oral risks. Acute studies in reported no deaths at 50 mg/kg orally, though respiratory depression emerged at elevated intravenous doses. Chronic exposure data remain sparse for isolated 7-hydroxymitragynine. , canine, and feline studies up to 6 weeks showed minimal from intraperitoneal or oral doses below thresholds eliciting opioid-like effects, with no significant histopathological changes noted. As a potent at mu-opioid receptors, 7-hydroxymitragynine may confer a lower risk of respiratory depression compared to full agonists like , based on biased signaling profiles observed , though direct comparative confirmation is lacking. Human data are absent for pure 7-hydroxymitragynine; reported kratom-related fatalities often involve poly-substance use, with 7-hydroxymitragynine concentrations rarely exceeding those in non-fatal cases, complicating attribution. Dependence potential stems from its high-affinity mu- agonism and metabolic role as an active mitragynine derivative. Rats self-administered 7-hydroxymitragynine intravenously at 5-10 mg/kg, an effect antagonized by mu- and delta- blockers, indicating reinforcing properties via endogenous opioid pathways. Intracranial self-stimulation assays in rats revealed no threshold-lowering reward facilitation at low doses (0.1-1 mg/kg intraperitoneally), but aversive effects at 3.2 mg/kg, contrasting with morphine's rewarding profile and suggesting dose-dependent over . Self-administration persistence implies abuse liability, potentially amplified by CYP3A4-mediated conversion from in users with variable activity. Withdrawal profiles lack direct human trials for 7-hydroxymitragynine. models infer opioid-like dependence from receptor engagement, with naloxone-precipitated withdrawal observed in mitragynine-exposed , attributable in part to 7-hydroxymitragynine formation. In kratom users, cessation yields symptoms such as anxiety, , and gastrointestinal distress—milder and shorter than classic —but these confound isolation of 7-hydroxymitragynine's contribution given its low natural abundance (typically <0.02% in leaves). Epidemiological surveys report kratom dependence meeting criteria in subsets of chronic users, with craving and fatigue prominent after dose omission, though causality to 7-hydroxymitragynine versus other alkaloids remains unparsed without controlled isolation studies. Overall, evidence supports moderate dependence risk, tempered by absence of robust rewarding signals in some paradigms.

Potential Therapeutic Applications

Analgesia and Pain Management

7-Hydroxymitragynine acts as a at the mu-opioid receptor (), exhibiting higher binding affinity and potency compared to its parent compound , which contributes to its properties. assays demonstrate that 7-hydroxymitragynine has approximately 9-fold greater affinity for the human than and functions as a low-efficacy with maximal around 20% relative to full agonists like DAMGO. This biased agonism favors G-protein signaling over beta-arrestin pathways, potentially yielding with reduced side effects such as respiratory depression observed in traditional opioids. Preclinical studies in confirm potent antinociceptive effects of 7-hydroxymitragynine in models of acute , including tail-flick and hot-plate tests, where produced dose-dependent analgesia naloxone-reversible via activation. In these assays, 7-hydroxymitragynine displayed 13-fold greater potency than and up to 46-fold greater than , with effective doses as low as 0.3-1 mg/kg subcutaneously in mice. at 5-10 mg/kg also elicited significant relief, surpassing morphine's efficacy in some metrics, though tolerance developed upon repeated dosing similar to opioids. These findings position 7-hydroxymitragynine as a key mediator of kratom's overall activity, arising as an of via hepatic oxidation. Human evidence for 7-hydroxymitragynine's role in derives primarily from observational data on kratom consumption, where users report substantial relief from conditions, often attributing effects to metabolites including 7-hydroxymitragynine. Surveys of kratom consumers indicate that over 90% use it for of , with frequent reports of reduced reliance on prescription opioids; a 2024 study of patients found significant self-reported improvements in scores and function following kratom initiation. However, no randomized controlled trials have evaluated isolated 7-hydroxymitragynine for analgesia in humans, limiting causal attribution and highlighting the need for clinical validation amid variables like variable content in products. Pharmacokinetic data suggest low natural concentrations in kratom (typically <0.1% of total alkaloids) necessitate metabolic conversion or enhanced extracts for pronounced effects.

Opioid Use Disorder and Withdrawal Aid

7-Hydroxymitragynine exhibits high-affinity agonism at mu-opioid receptors, with potency reported as approximately 13- to 46-fold greater than morphine in analgesic assays, providing a pharmacological basis for potential mitigation of opioid withdrawal symptoms through receptor occupancy and alleviation of dysphoria and physical signs such as muscle aches and anxiety. In animal models of dependence, kratom preparations containing mitragynine—which undergoes hepatic metabolism to 7-hydroxymitragynine—have suppressed naloxone-precipitated withdrawal behaviors in morphine-dependent rodents, suggesting that the metabolite contributes to substitution-like effects akin to partial opioid agonists used in maintenance therapy. However, direct preclinical evaluations of isolated 7-hydroxymitragynine in opioid withdrawal paradigms remain scarce, limiting causal attribution to this specific alkaloid. Human data derive primarily from observational surveys of kratom users, many of whom report employing the plant or its extracts—implicitly involving 7-hydroxymitragynine as the key active component—to self-manage symptoms, including reducing cravings and easing acute withdrawal from substances like or prescription opioids. These accounts, drawn from self-selected samples, indicate subjective relief in up to 40-50% of respondents with prior opioid dependence histories, though methodological limitations such as and absence of controls undermine reliability. No randomized controlled trials have assessed 7-hydroxymitragynine or concentrated derivatives for , and clinical guidelines do not endorse it due to insufficient evidence of efficacy or safety profiles comparable to established treatments like . Concentrated 7-hydroxymitragynine products, often synthesized or extracted for higher potency than natural kratom leaf, have been explicitly marketed since around 2023 as aids for , with vendors claiming reduced tolerance buildup relative to full synthetic s. Yet, pharmacodynamic reveal full at mu-receptors without the ceiling effects of partial agonists, heightening risks of respiratory depression, overdose, and that could complicate transition to or standard pharmacotherapies. Regulatory assessments highlight associations with severe illnesses, including seizures and hospitalizations, in users seeking withdrawal relief, attributing harms to unpredictable dosing and adulteration rather than inherent inefficacy. Long-term use may substitute rather than resolve dependence, as evidenced by reports of kratom withdrawal syndromes mirroring , prompting calls for strategies over unverified substitution.

Risks and Adverse Effects

Acute Toxicity and Overdose Risks

In animal models, 7-hydroxymitragynine demonstrates low acute oral toxicity, with no lethality observed in mice administered doses ranging from 6.25 to 50 mg/kg, precluding calculation of an oral LD50 value. Intravenous administration yields an LD50 of 24.7 mg/kg in mice, comparable to heroin (23.7 mg/kg), primarily due to rapid-onset respiratory depression and seizures occurring within 20 minutes. Preclinical studies further indicate potent mu-opioid receptor agonism leading to dose-dependent respiratory depression in rats, exceeding morphine's potency by over threefold, though reversible with naloxone. Human data on isolated 7-hydroxymitragynine overdose remains limited, as most exposures occur via kratom products where it serves as a minor or ; however, concentrated semi-synthetic 7-hydroxymitragynine products, often sold as high-potency pills or tablets labeled "7-OH" or "70H," elevate risks due to their estimated 10- to 46-fold greater potency over and up to 13-fold potency relative to morphine. These products, distinct from traditional kratom leaves containing only trace amounts (<0.1–2%), are marketed for pain relief, anxiety, mood enhancement, or opioid withdrawal but contribute to an emerging public health concern amid the opioid crisis, with heightened potential for addiction, overdose involving respiratory depression, and severe side effects. Acute overdose symptoms mirror , including , nausea, vomiting, pinpoint pupils, apnea, and altered mental status, as seen in a case of high-dose kratom ingestion (approximately 4.8 g equivalents) reversed by 2 mg intravenous . Severe outcomes such as , seizures, or rebound hypoxia may occur, but empirical evidence shows no established lethal threshold, with fatalities exceedingly rare in single-substance exposures and typically involving polysubstance use (e.g., , benzodiazepines). Rising reports of 7-hydroxymitragynine-enriched products correlate with increased severe exposures, including 3 major outcomes among 53 U.S. poison center cases from early 2025 and tripling of detected fatalities from 2019-2022 to 2023-2025, though causation is confounded by under-detection in toxicology screens focused on and frequent co-ingestants. effectively mitigates acute effects, suggesting a therapeutic window wider than classical opioids, but high-potency formulations may narrow this margin absent polysubstance factors.

Long-Term Dependence and Withdrawal

Preclinical studies in rodents demonstrate that 7-hydroxymitragynine induces , tolerance, and withdrawal symptoms through its action as a potent mu-opioid receptor . In ddY mice treated subcutaneously with 7-hydroxymitragynine at doses of 2.5–10 mg/kg, chronic administration led to antinociceptive tolerance, evidenced by diminished tail-flick response latency compared to acute dosing, and bidirectional cross-tolerance with . Naloxone-precipitated withdrawal (at 3 mg/kg) produced signs equivalent in severity to those from chronic treatment, including increased jumping behavior, rearing, , and body . In rats, 7-hydroxymitragynine (0.3–3 mg/kg) fully substituted for in drug discrimination paradigms and supported intravenous self-administration (5–10 μg/infusion), behaviors blocked by mu- and delta-opioid antagonists, confirming reinforcing effects and abuse liability. Human evidence on isolated 7-hydroxymitragynine remains limited, with long-term dependence primarily inferred from its role as an in kratom () and emerging semi-synthetic products. Concentrated 7-OH formulations, far more potent than traditional kratom, heighten addiction potential due to direct and intense mu-opioid agonism, bypassing the slower metabolic conversion from . In kratom users exhibiting high dependence—often consuming 5–20 g daily for months to years—withdrawal symptoms onset 1–48 hours after cessation, including , , , anxiety, , , and hot flashes, typically resolving in 3–10 days without intervention. These effects, milder and less consistent than classic , occur in under 10% of surveyed U.S. users but rise among those with prior . For purified or concentrated 7-hydroxymitragynine, unlike kratom extracts that produce balanced stimulant and sedative effects with milder opioid action, these products elicit intense opioid-like effects including analgesia, euphoria, and sedation, with anecdotal reports and poison center data (e.g., 53 cases from February–May 2025) describing more pronounced opioid-like withdrawal, potentially exacerbated by its 13-fold higher mu-opioid affinity relative to and circumvention of kratom's slower metabolic conversion from , alongside higher risks of dependence and adverse events. Health authorities distinguish high-potency 7-hydroxymitragynine products from natural kratom due to greater abuse potential; neither is FDA-approved. No controlled long-term human trials exist, but animal models suggest risks of escalating tolerance and severe syndromes with repeated high-potency exposure, distinct from kratom's mixed profile that may attenuate dependence via partial agonism and adrenergic modulation. Dependence severity correlates with dose, duration, and individual factors like concurrent substance use, with males reporting more symptoms independent of intake levels in observational kratom cohorts.

Confounding Factors in Reported Harms

Reported harms associated with 7-hydroxymitragynine, primarily derived from kratom consumption or synthetic analogs, often fail to isolate the compound's causal role due to prevalent polydrug interactions. In analyses of fatalities involving kratom alkaloids, including and its 7-hydroxymitragynine, the majority feature concurrent use of opioids, benzodiazepines, or stimulants, complicating attribution of death to kratom alone; this pattern is amplified in concentrated 7-OH products, where reported deaths—sometimes linked to respiratory depression and overdose—frequently involve mixes with other drugs, contributing to their status as an emerging threat in the opioid crisis. For instance, toxicological reviews indicate that kratom is frequently detected in contexts where users self-medicate for withdrawal, with polydrug exposures present in over 90% of such cases, thus confounding direct toxicity assessments. This pattern underscores how underlying or polysubstance regimens, rather than 7-hydroxymitragynine in isolation, may drive adverse outcomes, though high-potency semi-synthetic forms distinct from traditional kratom warrant separate scrutiny for their amplified risks. Product adulteration and variability in alkaloid concentrations represent additional confounders, as unregulated kratom products or synthetic 7-hydroxymitragynine formulations can contain elevated or inconsistent levels of active compounds, exceeding those in natural leaves. Natural kratom typically yields low 7-hydroxymitragynine concentrations (via hepatic metabolism of ), but synthetic variants or contaminated extracts amplify potency and risks, with FDA warnings highlighting severe events linked to such adulterated "7-OH" products rather than traditional preparations. Variability in -to-7-hydroxymitragynine ratios across products further obscures harm causality, as higher-dose or impure samples correlate with reported toxicities absent in standardized, lower-potency uses. Pre-existing health conditions and practices also confound reported adverse effects, with users often employing kratom for or opioid cessation amid comorbidities like or psychiatric disorders. Case reports of , such as seizures or dependence, rarely control for these factors, potentially misattributing symptoms to 7-hydroxymitragynine when baseline vulnerabilities or withdrawal from primary s predominate. Moreover, post-mortem instability of 7-hydroxymitragynine in biological samples limits accurate quantification, leading to interpretive errors in where serves as a proxy, potentially inflating perceived risks from kratom-derived metabolites. Methodological limitations in surveillance data exacerbate these issues, as voluntary reporting systems like poison center logs or FDA adverse event databases lack denominators for exposure prevalence and often omit comprehensive toxicology, biasing toward severe cases while underrepresenting benign or self-resolving effects like nausea. Peer-reviewed critiques note that such datasets, influenced by regulatory narratives, rarely adjust for confounders like dose-response thresholds or user demographics, with most acute harms tied to excessive intake rather than inherent compound toxicity at therapeutic levels. This selective emphasis, without rigorous controls, parallels patterns in other natural product assessments where empirical isolation of harms proves challenging.

United States Federal Developments

In August 2016, the (DEA) issued a notice of intent to temporarily place and 7-hydroxymitragynine into Schedule I of the , citing high potential for abuse and lack of accepted medical use. The proposal faced significant public opposition, including over 23,000 comments, leading the DEA to withdraw it in October 2016 without finalizing the scheduling. As of October 2025, neither compound has been permanently scheduled federally, though the DEA continues to monitor kratom products containing them as substances of concern. The (FDA) has maintained that 7-hydroxymitragynine lacks safety data for use in dietary supplements or foods and has issued multiple warnings against kratom-derived products due to risks of addiction, seizures, and death when adulterated or concentrated. On July 15, 2025, the FDA sent warning letters to seven companies marketing 7-hydroxymitragynine-infused gummies, drinks, and powders, asserting violations of the Federal Food, Drug, and Cosmetic Act since no FDA-approved drugs contain the compound and it is ineligible for supplement status. In July 2025, the FDA announced targeted restrictions on concentrated 7-hydroxymitragynine products—distinct from natural kratom leaf—citing their potent effects and rising exposures reported to centers (1,690 kratom-related and 165 specifically 7-hydroxymitragynine in early 2025). By late September 2025, the FDA formally recommended to the DEA that 7-hydroxymitragynine be classified as a under the Controlled Substances Act akin to other s, emphasizing enforcement against synthetic or isolated forms while exempting traditional kratom leaf preparations. In December 2025, the FDA conducted seizures of 7-OH opioid products targeting concentrated forms due to public health risks including addiction, overdose, and respiratory depression. No such scheduling has been enacted as of October 26, 2025, but the actions reflect ongoing federal scrutiny amid limited evidence of isolated 7-hydroxymitragynine fatalities (none confirmed solely from the compound).

State-Level Regulations

In states where kratom () is fully prohibited, 7-hydroxymitragynine—a key responsible for much of its pharmacological activity—is likewise illegal, typically classified alongside as a Schedule I under state controlled substances acts. As of October 2025, complete bans apply in , , , , , , and , where possession, sale, distribution, or manufacture of kratom products containing 7-hydroxymitragynine carries criminal penalties equivalent to other unauthorized opioids. Louisiana's ban, enacted in 2025, explicitly targets kratom and its psychoactive components, including 7-hydroxymitragynine, following reports of associated health risks. Other states regulate rather than ban 7-hydroxymitragynine through frameworks like the Model Kratom Consumer Protection Act, adopted in jurisdictions such as Georgia, , and , which mandate product testing for contaminants, accurate labeling of alkaloid content, and age restrictions (typically 21+ for purchase). These laws often cap 7-hydroxymitragynine concentrations to mitigate potency risks, such as Georgia's limit of no more than 2% by weight in commercial products and the Utah Kratom Consumer Protection Act (Utah Code § 4-45-104), which prohibits kratom products containing a level of 7-hydroxymitragynine (7-OH) in the alkaloid fraction greater than 2% of the alkaloid composition, to prevent adulteration or overdose potential. Colorado enacted SB25-072 in 2025, limiting high-potency kratom products exceeding 2% 7-hydroxymitragynine following safety concerns and fatalities. , while not banning kratom outright, issued an emergency rule on August 13, 2025, prohibiting the sale, possession, or distribution of isolated or concentrated forms of 7-hydroxymitragynine outside natural kratom leaf matrices, citing concerns from synthetic isolates. The table below summarizes state-level status for 7-hydroxymitragynine as of October 2025, based on its inclusion in kratom prohibitions or specific alkaloid scheduling:
StatusStatesKey Provisions
Prohibited (Schedule I or equivalent ban), , , , , , Criminal penalties for possession/sale; targets and 7-hydroxymitragynine explicitly.
Regulated (age limits, labeling, concentration caps)Georgia, , , , , , , (among 17 total with KCPA-like laws)Requires third-party testing; limits on 7-hydroxymitragynine content (e.g., ≤2% in Georgia, limits on high-potency forms exceeding 2% in Colorado); sales to minors banned.
Unregulated (legal without state restrictions)Remaining 26 states (e.g., , , )Subject only to federal oversight; local bans possible in cities like , CA.
Regulatory divergence reflects debates over 7-hydroxymitragynine's opioid-like effects versus anecdotal claims, with bans driven by data from poison control centers rather than comprehensive clinical trials. At least 24 states plus the District of Columbia impose some form of oversight, up from prior years amid rising scrutiny of concentrated extracts.

International Perspectives

7-Hydroxymitragynine is not controlled under any drug control conventions, nor has it been scheduled by the following a pre-review of kratom, , and 7-hydroxymitragynine in 2021 that did not lead to recommendations for international scheduling. Its regulatory status internationally aligns closely with that of kratom (), as 7-hydroxymitragynine constitutes a minor but potent within the plant; where kratom is prohibited, possession, sale, or use of 7-hydroxymitragynine is typically also restricted. In , no EU-wide prohibition exists, though the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) monitors kratom and its alkaloids due to emerging reports of adverse effects, and the (EFSA) has assessed potential health risks from consumption, concluding insufficient data for safety but noting opioid-like properties. Individual member states vary: bans on kratom—and thus 7-hydroxymitragynine—apply in countries including , , , , , , , and , often classifying it under general psychoactive substance controls or new psychoactive substance laws. explicitly designates and 7-hydroxymitragynine as Schedule 1 controlled drugs, the highest restriction level, prohibiting all activities related to their production, possession, or supply. Outside Europe, has prohibited since 2005, with offenses for possession or supply carrying penalties up to two years imprisonment, effectively banning 7-hydroxymitragynine as a component . In , and 7-hydroxymitragynine have been classified as controlled substances since 2013, rendering kratom products illegal. Several Asian countries maintain strict bans, including , , , , and , where kratom imports and use are criminalized under narcotic laws, though enforcement focuses on the plant rather than isolated alkaloids. In kratom's Southeast Asian countries of origin, perspectives have shifted toward rather than outright : decriminalized kratom in 2021 for traditional and medical use under licensed conditions, while legalized it in 2020 for pharmaceutical development and export, potentially allowing controlled access to natural 7-hydroxymitragynine levels but restricting concentrated or synthetic forms. These developments reflect empirical recognition of kratom's cultural role and potential therapeutic applications amid limited evidence of widespread harm, contrasting with precautionary bans elsewhere driven by isolated toxicity reports.

Controversies and Debates

Regulatory Actions and Critiques

In July 2025, the U.S. Food and Drug Administration (FDA) issued warning letters to seven companies marketing products containing 7-hydroxymitragynine (7-OH), deeming them adulterated conventional foods or unapproved new drugs due to the compound's failure to meet safety standards for such categories and its high potential for abuse stemming from potent opioid receptor binding. On July 29, 2025, the FDA escalated efforts by recommending that the Drug Enforcement Administration (DEA) temporarily place 7-OH into Schedule I under the Controlled Substances Act via emergency scheduling, citing its emergence as a concentrated opioid threat distinct from natural kratom leaf; this followed a 2016 DEA intent to schedule both mitragynine and 7-OH, which was withdrawn after public comments highlighted incomplete scientific data. The DEA is reviewing this recommendation, which would prohibit non-research possession, distribution, or manufacture without full rulemaking. At the state level, Florida's implemented an emergency rule on August 13, 2025, classifying isolated and concentrated 7-OH as a Schedule I substance, equating it legally to or and immediately banning its sale or possession outside research contexts. Vermont has included 7-OH in its Regulated Drug Rule, subjecting it to state oversight akin to controlled substances. These actions reflect a patchwork approach, with several states targeting kratom derivatives amid federal deliberation, potentially complicating interstate commerce and enforcement. Critiques of these measures emphasize a lack of empirical support for blanket restrictions, noting no confirmed fatalities attributable solely to 7-OH despite its market availability and over 50 reports in the FDA's system, which often involve polydrug use or pre-existing conditions. Experts and advocacy groups, including those citing FDA Adverse Event Reporting System data, argue for evidence-based regulation over emergency scheduling, pointing to the 2016 withdrawal as precedent for awaiting fuller toxicological profiles rather than preempting based on pharmacological affinity alone. Such positions contend that targeting synthetic or concentrated isolates risks overreach without addressing natural kratom's lower 7-OH content or potential therapeutic roles in , while fragmented state-federal rules foster regulatory inconsistency and black-market incentives.

Empirical Evidence vs. Public Health Narratives

Public health authorities, including the U.S. (FDA), have characterized 7-hydroxymitragynine (7-OH) as a potent agonist presenting an emerging threat due to risks of , overdose, and severe adverse events such as seizures and respiratory depression, particularly in concentrated products marketed as dietary supplements. The FDA has issued warnings since 2025 highlighting one reported death and multiple illnesses linked to 7-OH-containing items, emphasizing its distinction from natural kratom leaf and lack of approval for any medical or supplemental use. These narratives often frame 7-OH within broader kratom concerns, associating it with and crises akin to synthetic opioids, despite limited direct causation data. In contrast, preclinical empirical data from animal studies reveal low acute toxicity for 7-OH, with oral LD50 values in rodents ranging from 200–591 mg/kg, far exceeding doses equivalent to human consumption levels in traditional kratom preparations where 7-OH occurs as a minor metabolite (typically <0.02% of leaf content). Acute and subchronic toxicity assessments in rodents, dogs, and cats demonstrate minimal adverse effects at doses up to 100 mg/kg, with no significant hepatotoxicity, nephrotoxicity, or mortality observed below lethal thresholds, unlike full mu-opioid agonists such as morphine. Pharmacodynamic studies confirm 7-OH's role as a high-affinity partial agonist at mu-opioid receptors, producing analgesia comparable to or exceeding mitragynine but with evidence of reduced respiratory depression and gastrointestinal side effects in vitro and in vivo, attributed to biased agonism and G-protein signaling bias over beta-arrestin pathways. Epidemiological and observational evidence further diverges from alarmist portrayals, as kratom-associated fatalities—often invoked in 7-OH discussions—involve in over 90% of cases, with pure 7-OH or rarely implicated as sole causes per reviews. pharmacokinetic data indicate rapid metabolism of precursor to 7-OH, but steady-state levels in users remain sub-toxic, supporting claims in self-reported surveys where low-dose kratom mitigates without equivalent dependence liability. Critiques of stances note overreliance on reports susceptible to (e.g., adulterated extracts) and underemphasis on dose-dependent , as isolated high-purity 7-OH products—targeted in recent FDA actions—deviate from ethnobotanical contexts where is negligible. This discrepancy underscores a narrative driven by precautionary regulatory impulses rather than comprehensive , with peer-reviewed syntheses affirming 7-OH's atypical profile favoring therapeutic exploration over blanket prohibition.

User Experiences and Harm Reduction Claims

Users report experiencing potent analgesia, mood enhancement, relaxation, , reduced anxiety, and from 7-hydroxymitragynine, with effects onsetting within 15-30 minutes and lasting 3-6 hours at typical doses of 5-10 mg. These subjective benefits are often cited in anecdotal accounts as reasons for use in self-managing or symptoms, though such reports derive primarily from online forums and lack controlled validation. Higher doses, up to 20 mg daily, may intensify but frequently lead to discomfort, including overstimulation or dysphoric agitation rather than calming effects. Adverse user experiences predominate in self-reports, highlighting rapid tolerance buildup after daily use and severe withdrawal upon cessation, often described as more protracted than with traditional opioids—potentially lasting weeks to months. Common withdrawal symptoms include intense mood swings, restless leg syndrome, prolonged insomnia, gastrointestinal distress, irritability, and cravings, with some users recounting life-disrupting dependence after brief exposure to concentrated products like tablets or extracts. Isolated cases link 7-hydroxymitragynine-containing items to acute events such as seizures, underscoring risks from unregulated dosing in over-the-counter formulations. Harm reduction claims among users emphasize conservative dosing—starting at 2.5-5 mg for novices, spacing administrations by at least 4 hours, and avoiding daily escalation—to minimize tolerance and dependence. Proponents argue that, unlike full opioids, 7-hydroxymitragynine offers a lower respiratory depression threshold at therapeutic levels, positioning it as a withdrawal aid or alternative, though clinical data indicate with opioids and naloxone-reversible overdoses in polysubstance contexts. Treatment-oriented strategies include supervised tapering and substitution with or , which have facilitated withdrawal management in documented cases, but user forums stress professional oversight due to the compound's 14-22-fold greater potency over at mu-opioid receptors. These practices remain unstandardized, with anecdotal sources potentially underreporting long-term sequelae amid self-selection bias toward positive initial outcomes.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC6598159/
  2. https://pubchem.ncbi.nlm.nih.gov/compound/7-Hydroxymitragynine
  3. https://pubmed.ncbi.nlm.nih.gov/31263758/
  4. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.751656/full
  5. https://www.sciencedirect.com/science/article/pii/S0022356524257645
  6. https://pubmed.ncbi.nlm.nih.gov/29949228/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC7542979/
  8. https://www.sciencedirect.com/science/article/abs/pii/S0376871625001541
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC8328003/
  10. https://www.smolecule.com/products/s1789903
  11. https://precision.fda.gov/ginas/app/ui/substances/c50748a1-8231-42ad-a263-6abc6bc49005
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC6272646/
  13. https://scholarscompass.vcu.edu/context/frsc_projects/article/1046/viewcontent/The_Analysis_of_Commercially_Available_Kratom_Products_in_Richmond__Virginia.pdf
  14. https://pubmed.ncbi.nlm.nih.gov/37518950/
  15. https://www.sciencedirect.com/science/article/pii/S1369526624000918
  16. https://reporter.nih.gov/project-details/10981335
  17. https://www.sciencedirect.com/science/article/pii/S2307410825000252
  18. https://www.jstage.jst.go.jp/article/cpb/70/9/70_c22-00441/_html/-char/en
  19. https://onlinelibrary.wiley.com/doi/full/10.1002/anie.202303700
  20. https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.058605
  21. https://www.nature.com/articles/s41598-020-76119-w
  22. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764885/full
  23. https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01273
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC7676998/
  25. https://scholars.uthscsa.edu/en/publications/interactive-effects-of-m-opioid-and-adrenergic-asub2sub-receptor-
  26. https://scholars.uthscsa.edu/en/publications/in-vitro-and-in-vivo-pharmacology-of-kratom
  27. https://www.nature.com/articles/s41467-021-23736-2
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC9314834/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC9235362/
  30. https://pubmed.ncbi.nlm.nih.gov/33847897/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC10934259/
  32. https://www.researchgate.net/publication/262536612_Evaluation_of_In_Vitro_Absorption_Distribution_Metabolism_and_Excretion_ADME_Properties_of_Mitragynine_7-Hydroxymitragynine_and_Mitraphylline
  33. https://pubmed.ncbi.nlm.nih.gov/34759012/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC4425236/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC7737207/
  36. https://www.wjgnet.com/2220-3192/full/v11/i3/16.htm
  37. https://pubs.acs.org/doi/10.1021/acsptsci.3c00335
  38. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.805986/full
  39. https://www.mdpi.com/1420-3049/29/5/984
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC9041851/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC7645423/
  42. https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2025.1653916/full
  43. https://www.sciencedirect.com/science/article/abs/pii/S0278691524004794
  44. https://www.hielscher.com/ultrasonic-kratom-extraction.htm
  45. https://www.ukm.my/mjas/v15_n1/Goh.pdf
  46. https://www.sciencedirect.com/science/article/pii/S1359511324001272
  47. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3906
  48. https://csp.pharmacy.ufl.edu/research/kratom/
  49. https://news.cuanschutz.edu/news-stories/what-is-7-oh-and-why-is-it-being-targeted-in-kratom-products
  50. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers
  51. https://www.fda.gov/consumers/consumer-updates/products-containing-7-oh-can-cause-serious-harm
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC5135684/
  53. https://pubmed.ncbi.nlm.nih.gov/40762659/
  54. https://pubmed.ncbi.nlm.nih.gov/14969718/
  55. https://www.sciencedirect.com/science/article/abs/pii/S0024320505008167
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC12140000/
  57. https://pubmed.ncbi.nlm.nih.gov/38474495/
  58. https://link.springer.com/article/10.1007/s00213-024-06734-2
  59. https://pubmed.ncbi.nlm.nih.gov/39644381/
  60. https://www.fda.gov/files/drugs/published/7-hydroxymitragynin_7-oh_an_assessment_of_the_scientific_data_and_toxicological_concerns_around_an_emerging_opioid_threat.pdf
  61. https://www.dshs.texas.gov/news-alerts/serious-illnesses-associated-7-oh-use
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC6662923/
  63. https://cdn.who.int/media/docs/default-source/controlled-substances/unedited--advance-copy-44th-ecdd-review-report_kratom.pdf
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC7923387/
  65. https://www.sciencedirect.com/science/article/abs/pii/S0024320503011664
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC5601368/
  67. https://www.sciencedirect.com/science/article/abs/pii/S1526590024007041
  68. https://kslegislature.gov/li_2024/b2023_24/committees/ctte_h_fed_st_1/documents/testimony/20230201_13.pdf
  69. https://www.sciencedirect.com/science/article/pii/S2772724623000124
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC3670991/
  71. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1416689/full
  72. https://www.mayoclinic.org/diseases-conditions/prescription-drug-abuse/in-depth/kratom-opioid-withdrawal/art-20402170
  73. https://www.medscape.com/viewarticle/legal-morphine-rise-kratom-and-7-oh-us-2025a1000cco
  74. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15832
  75. https://dig.pharmacy.uic.edu/faqs/2023-2/august-2023-faqs/what-data-exists-on-the-use-of-buprenorphine-and-buprenorphine-naloxone-for-the-treatment-of-kratom-withdrawal/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC10408695/
  77. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1403140/full
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC10311168/
  79. https://pubmed.ncbi.nlm.nih.gov/37270449/
  80. https://pubmed.ncbi.nlm.nih.gov/24698080/
  81. https://onlinelibrary.wiley.com/doi/10.1111/add.16728
  82. https://www.sciencedirect.com/science/article/abs/pii/S0376871624002503
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC11153780/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC11180979/
  85. https://www.dea.gov/factsheets/kratom
  86. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
  87. https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letters-firms-marketing-products-containing-7-hydroxymitragynine
  88. https://www.cbsnews.com/sacramento/news/fda-pushes-to-ban-chemical-found-in-kratom/
  89. https://www.fda.gov/news-events/press-announcements/fda-seizes-7-oh-opioids-protect-american-consumers
  90. https://www.venable.com/insights/publications/2025/08/fda-announces-plan-to-restrict-7-oh-opioid
  91. https://legislativeanalysis.org/wp-content/uploads/2025/07/Kratom-Summary-of-State-Laws.pdf
  92. https://stateline.org/2025/08/11/kratom-faces-increasing-scrutiny-from-states-and-the-feds/
  93. https://statecapitallobbyist.com/kratom/kratom-regulation-in-2025-comprehensive-legislative-updates-across-the-u-s/
  94. https://leg.colorado.gov/bills/sb25-072
  95. http://www.myfloridalegal.com/newsrelease/attorney-general-james-uthmeier-files-emergency-rule-immediately-removing-dangerous-7
  96. https://www.quick.md/quick-tips/kratom-ban-update/
  97. https://legislativeanalysis.org/kratom-summary-of-state-laws/
  98. https://rockinst.org/blog/on-kratom-or-the-fractured-regulation-of-unscheduled-drugs/
  99. https://www.who.int/publications/m/item/kratom-mitragynine-7-hydroxymitragynine-critical-review-report
  100. https://www.euda.europa.eu/publications/drug-profiles/kratom_en
  101. https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2022.e200415
  102. https://www.publichealthtoxicology.com/Kratom-use-Overview-risks-and-cautions%2C201331%2C0%2C2.html
  103. https://tiogaasap.org/kratom/
  104. https://www.abc.net.au/news/2024-12-07/kratom-use-is-united-states-causing-controversy/104689476
  105. https://www.lexology.com/library/detail.aspx?g=db6f3ba8-a2c5-4fb2-89b8-ab93d1b09b23
  106. https://bulkkratomnow.com/kratom-in-israel-what-is-the-current-legal-status/
  107. https://buykratom.us/where-is-kratom-illegal-kratom-laws-around-the-world/
  108. https://www.tni.org/en/article/kratom-in-myanmar-and-southeast-asia-time-for-legal-regulation
  109. https://www.regulations.gov/docket/DEA-2016-0015/document
  110. https://www.reuters.com/press-releases/experts-call-for-evidence-based-7oh-regulation-2025-07-07/
  111. https://ssdp.org/blog/sssdp-statement-on-7-oh-scheduling/
  112. https://pubs.acs.org/doi/10.1021/acscentsci.9b00141
  113. https://pubs.acs.org/doi/10.1021/acsptsci.4c00277
  114. https://www.researchgate.net/publication/353468468_A_systematic_review_of_preclinical_studies_on_the_therapeutic_potential_and_safety_profile_of_kratom_in_humans
  115. https://refinerecovery.com/7oh/
  116. https://pharmacy.uconn.edu/course/kratom/
  117. https://www.reddit.com/r/TooAfraidToAsk/comments/1k12i02/what_is_7oh_like/
  118. https://adai.uw.edu/wordpress/wp-content/uploads/dlm_uploads/Kratom-202404.pdf
  119. https://www.reddit.com/r/addiction/comments/1lfpxfw/7hydroxymitragynine_ruined_my_life/
  120. https://www.reddit.com/r/philadelphia/comments/1mp1kgv/7oh_kratom_is_fueling_addictions_across_the/
  121. https://www.reddit.com/r/greenville/comments/1mtpxfg/i_had_a_seizure_after_taking_a_legal_mood_booster/
Add your contribution
Related Hubs
User Avatar
No comments yet.